

**AMENDMENTS TO THE CLAIMS**

1. (Currently amended): A method for generating clinically relevant numbers of Th2 cells, comprising:
  - (a) collecting T-cells from the peripheral blood mononuclear cells of a mammal;
  - (b) stimulating the T-cells to induce differentiation into Th2 cells, wherein the cells are stimulated by two or more monoclonal antibodies in the absence of exogenous IL-2 and in the presence of one or more agents selected from the group consisting of IL-4, anti-IFN- $\gamma$  monoclonal antibody, and anti-IL-12 monoclonal antibody; and
  - (c) expanding the cells to at least  $10^8$  cells/milliliter, wherein the cells are a ~~homogenous~~ homogeneous population of Th2 cells.
2. (canceled)
3. (previously presented): The method of claim 1, wherein the Th2 cells are specific for a defined antigen.
4. (canceled)
5. (Currently amended): The method of claim 1, wherein the expanded Th2 cells do not require exogenous IL-2.
- 6-7. (canceled)
8. (Currently amended): The method of claim 7, wherein the monoclonal antibodies are specific for CD3 or CD2, combined with any combination of monoclonal antibodies specific for one or more of the following: CD4, CD8, CD11a, CD27, CD28, and CD44 ~~and CD45RO~~.
9. (previously presented): The method of claim 1, wherein the cells are expanded in a hollow fiber bioreactor or a culture bag.
- 10-11. (canceled)

12. (original): The method of claim 1, wherein the mammal is a human.

13-101. (canceled)